Literature DB >> 9396392

Chemosensitive gliomas in adults: which ones and why?

W Mason, D N Louis, J G Cairncross.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396392     DOI: 10.1200/JCO.1997.15.12.3423

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.

Authors:  H Roche; H Cure; A Adenis; P Fargeot; C Terret; M A Lentz; J C Madelmont; P Fumoleau; A Hanausk; P Chollet
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

2.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

3.  Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.

Authors:  Stephen Yip; Yaron S Butterfield; Olena Morozova; Suganthi Chittaranjan; Michael D Blough; Jianghong An; Inanc Birol; Charles Chesnelong; Readman Chiu; Eric Chuah; Richard Corbett; Rod Docking; Marlo Firme; Martin Hirst; Shaun Jackman; Aly Karsan; Haiyan Li; David N Louis; Alexandra Maslova; Richard Moore; Annie Moradian; Karen L Mungall; Marco Perizzolo; Jenny Qian; Gloria Roldan; Eric E Smith; Jessica Tamura-Wells; Nina Thiessen; Richard Varhol; Samuel Weiss; Wei Wu; Sean Young; Yongjun Zhao; Andrew J Mungall; Steven J M Jones; Gregg B Morin; Jennifer A Chan; J Gregory Cairncross; Marco A Marra
Journal:  J Pathol       Date:  2011-11-10       Impact factor: 9.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.